Genprex Inc Surges Amid Market Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 04 Dec 25
Source: Coinmarketcap
Genprex Inc experienced a significant price increase of 23.67%, crossing above its 5-day SMA despite a downturn in the broader market.
The Nasdaq-100 and S&P 500 indices both reported losses, with the Nasdaq-100 down 0.31% and the S&P 500 down 0.08%. This backdrop of market weakness typically pressures stock prices, yet Genprex's performance stands out.
This movement may indicate strong investor interest or confidence in Genprex's future prospects, potentially setting the stage for further gains if market conditions improve.
Analyst Views on GNPX
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
